AstraZeneca promises more partnerships after Q3 results vindicate CEO’s patent deals strategy
After revealing that patent-based deals had helped to shore up its revenues and boost core operating profits in the third quarter of 2017, AstraZeneca has said it will continue its controversial strategy of selling stakes in and offering licences to…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.